Jagsonpal Pharmaceuticals Ltd. News and Updates

Keep track of all breaking news on Jagsonpal Pharmaceuticals Ltd. from all sources in a single place.

23 Feb 2025

222.13

1.04%

USFDA pulls up Jagsonpal Pharma for manufacturing lapses at API plant

Business Standard

The US health regulator has pulled up Jagsonpal Pharmaceuticals for significant manufacturing lapses at its Rajasthan-based active pharmaceutical ingredients (APIs) plant. In a warning letter issued to the company's Managing Director Manish Gupta, the US Food and Drug Administration (USFDA) noted that the correspondence summarizes significant deviations from Current Good Manufacturing Practice for APIs. The US health regulator stated that it inspected the company's Bhiwadi- based plant in Rajasthan on March 20, March 27, and April 3, 2024. "This warning letter summarises significant deviations from Current Good Manufacturing Practice (CGMP) for APIs. Because the methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API is adulterated," the USFDA stated in the warning letter. A warning letter issued by the USFDA usually identifies the violation, such as poor manufacturing practices, problems with claims for what a product ca

Jagsonpal Pharmaceuticals Ltd. has gained 71.85% in the last 1 Year

Jagsonpal Pharmaceuticals Ltd.

23 Jan 2025

222.13

1.04%

Jagsonpal Pharma shares jump 10% after stellar Q3 results; know more

Business Standard

Gurugram-based Jagsonpal Pharmaceuticals share price gained 10.3 per cent at Rs 252 a piece on the BSE in Thursday's intraday trade

Jagsonpal Pharmaceuticals Ltd. is trading above its 200 day SMA of 203.9

Jagsonpal Pharmaceuticals Ltd.

23 Jan 2025

222.13

1.04%

to see Rapid results content

Jagsonpal Pharmaceuticals Ltd.

23 Oct 2024

222.13

1.04%

to see Rapid results content

Jagsonpal Pharmaceuticals Ltd.

17 Oct 2024, 12:20PM

222.13

1.04%

Jagsonpal Pharma up 7% as co to consider Q2 results, stock-split on Oct 23

Business Standard

The uptick in Jagsonpal Pharma share price came after the company announced that its board of directors will meet on October 23 to consider Q2 and H1FY25 results and proposal for stock-split